Manhattan Pharmaceuticals To Focus On Dermatology After Obesity Candidate Fails
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will discontinue development of oral oleoyl-estrone for obesity after it failed to show a significant difference over placebo in Phase IIa studies.